clinical endpoint comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20 °C or below | Desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity and identity |
| Common synonyms | Thymalfasin, T alpha 1 | Sequence identical to natural fragment |
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
All octopuses and most cephalopods are considered to be color blind. Coleoid cephalopods (octopus, squid, cuttlefish) have a single photoreceptor type and lack the ability to determine color by comparing detected photon intensity across multiple spectral channels. When camouflaging themselves, they use their chromatophores to change brightness and pattern according to the background they see, but their ability to match the specific color of a background may come from cells such as iridophores and leucophores that reflect light from the environment. They also produce visual pigments throughout their body and may sense light levels directly from their body. Evidence of color vision has been found in the sparkling enope squid (Watasenia scintillans). It achieves color vision with three photoreceptors, which are based on the same opsin, but use distinct retinal molecules as chromophores: A1 (retinal), A3 (3-dehydroretinal), and A4 (4-hydroxyretinal). The A1-photoreceptor is most sensitive to green-blue (484 nm), the A2-photoreceptor to blue-green (500 nm), and the A4-photoreceptor to blue (470 nm) light. In 2015, a novel mechanism for spectral discrimination in cephalopods was described. This relies on the exploitation of chromatic aberration (wavelength-dependence of focal length). Numerical modeling shows that chromatic aberration can yield useful chromatic information through the dependence of image acuity on accommodation.
In addition to their role in RNAi, siRNAs can also activate gene expression, a phenomenon termed "RNA activation" or RNAa. This was first observed when synthetic siRNAs, termed "small activating RNA" (saRNA), targeting gene promoters were found to induce potent transcriptional activation of target genes. RNAa has been demonstrated to be a conserved mechanism, observed across species from insects, C. elegans, and plants, to mammals (including humans). The mechanism of RNAa involves the targeting of promoter regions by saRNAs, leading to the recruitment of transcriptional machinery and epigenetic changes that promote gene expression. This process often involves the RNA-induced transcriptional activation (RITA) complex, which includes Argonaute proteins (particularly Ago2), RNA helicase A (RHA), and CTR9. Endogenous miRNAs can also mediate RNAa, expanding the regulatory roles of these small RNAs beyond gene silencing. Several saRNA-based therapeutics are currently in clinical development. MTL-CEBPA, developed by MiNA Therapeutics, targets the CEBPA gene and is in Phase II trials for liver cancer. RAG-01, developed by Ractigen Therapeutics, targets the p21 gene and is in Phase I trials for non-muscle invasive bladder cancer (NMIBC). These clinical trials represent a significant step towards translating the RNAa phenomenon into novel therapeutic strategies.
This phenomenon can be used in practical applications like LED's and solar cells. In these technologies either the efficiency of absorption or emission is of critical importance and nanoparticles with an interfacial layer could be used to improve this efficiency by either absorbing or emitting at a wider range of energies.
Sources: en.wikipedia.org
1993/764) Value Added Tax (Increase of Consideration for Fuel) Order 1993 (S.I. 1993/765) Value Added Tax (Increase of Registration Limits) Order 1993 (S.I. 1993/766) Value Added Tax (Protective Boots and Helmets) Order 1993 (S.I. 1993/767) Registered Establishments (Fees) (Scotland) Order 1993 (S.I. 1993/768) Act of Sederunt (Interest in Sheriff Court Decrees and Extracts) 1993 (S.I. 1993/769) Act of Sederunt (Rules of the Court of Session Amendment) (Interest in Decrees and Extracts) 1993 (S.I. 1993/770) Water Undertakers (Rateable Values) (Amendment) Order 1993 (S.I. 1993/772) Council Tax (Administration and Enforcement) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/773) Non-Domestic Rating (Collection and Enforcement) (Amendment and Miscellaneous Provision) Regulations 1993 (S.I. 1993/774) Community Charges (Administration and Enforcement) (Amendment) Regulations 1993 (S.I. 1993/775) Pensions Increase (Review) Order 1993 (S.I. 1993/779) British Railways (Penalty Fares) Act 1989 (Activating No. 9) Order 1993 (S.I. 1993/780) British Railways (Penalty Fares) Act 1989 (Activating No. 10) Order 1993 (S.I. 1993/781) Premium Savings Bonds (Amendment) Regulations 1993 (S.I. 1993/782) National Savings Stock Register (Amendment) Regulations 1993 (S.I. 1993/783) Redundancy Payments (Local Government) (Modification) (Amendment) Order 1993 (S.I. 1993/784) Child Support Act 1991 (Consequential Amendments) Order 1993 (S.I. 1993/785) Chester Port Health Authority (Revocation)Order 1993 (S.I. 1993/786) Civil Legal Aid (Assessment of Resources) (Amendment) Regulations 1993 (S.I.
== Rechargeable batteries == Lithium carbonate-derived compounds are crucial to lithium-ion batteries. Lithium carbonate may be converted into lithium hydroxide as an intermediate. In practice, two components of the battery are made with lithium compounds: the cathode and the electrolyte. The electrolyte is a solution of lithium hexafluorophosphate, while the cathode uses one of several lithiated structures, the most popular of which are lithium cobalt oxide and lithium iron phosphate.
Raleigh's all-time record high temperature is 106 °F (41 °C) on July 5, 2024, while the all-time record low is −9 °F (−23 °C) on January 21, 1985. Raleigh falls in USDA hardiness zones 7b (5 °F to 10 °F) and 8a (10 °F to 15 °F).
== Treatment == Ciguatera poisoning is a treatable condition. Genetically susceptible individuals can develop a long-term illness due to inability to clear the Ciguatera toxins; these people can be treated using the protocol for Chronic Inflammatory Response Syndrome (CIRS). Acutely, the mainstay of treatment is supportive care, but once the toxin is identified, CIRS treatment should start as soon as possible, as it will speed recovery, even for those without the genetic susceptibility. There is some evidence that calcium channel blockers like nifedipine and verapamil are effective in treating some of the symptoms that remain after the initial sickness passes, such as poor circulation and shooting pains through the chest. These symptoms are due to vasoconstriction caused by maitotoxin and/or palytoxin. Ciguatoxin lowers the threshold for opening voltage-gated sodium channels in synapses of the nervous system. Opening a sodium channel causes depolarization, which could sequentially cause paralysis, vasoconstriction, and changing the senses of hot and cold. Some medications such as amitriptyline may reduce some symptoms, such as fatigue and paresthesia, although benefit does not occur in every case.
Sources: en.wikipedia.org
=== Affordable Care Act === Schmitt filed lawsuits to have the Affordable Care Act invalidated by courts. After Missouri voters approved a constitutional amendment to expand Medicaid coverage in the state, he argued that Republican lawmakers and Governor Mike Parson could legally refuse to implement the expansion. The Missouri Supreme Court rejected that position in a 2021 ruling.
== Clinical significance == The classical presentation of primary HHV-6b infection is as exanthema subitum (ES) or "roseola", featuring a high temperature lasting 3 to 5 days followed by a rash on the torso, neck, or face and sometimes febrile convulsions, however, the symptoms are not always present together. However, one study (1997) indicated that a rash is not a distinguishing feature of HHV-6 infection, with rates similar to non-HHV-6 infections (10–20% of febrile children in both groups). HHV-6 infections more frequently present with high temperatures (over 40C), at a rate of around two thirds compared to less than half in the non-HHV-6 patients. Similarly significant differences were seen in malaise, irritability, and tympanic membrane inflammation. Primary infection in adults tend to be more severe. Diagnosis for the virus, particularly HHV-6B, is vital for the patient because of the infection's adverse effects. Symptoms that point to this infection, such as rashes, go unnoticed in patients that receive antibiotics because they can be misinterpreted as a side-effect of the medicine. In addition to exanthema subitum HHV-6B is known to be associated with the hepatitis, febrile convulsions, and encephalitis. The virus periodically re-activates from its latent state, with HHV-6 DNA being detectable in 20–25% of healthy adults in the United States. In the immunocompetent setting, these re-activations are often asymptomatic, but in immunosuppressed individuals there can be serious complications.
DNA-binding domain (DBD) A protein domain containing at least one structural motif capable of recognizing and interacting with the nucleotides of a double-stranded or single-stranded DNA molecule. DNA-binding domains may bind to specific sequences or have a non-specific affinity for DNA. They are the primary functional components of DNA-binding proteins, including many transcription factors and regulatory proteins.
CASP, which stands for Critical Assessment of Techniques for Protein Structure Prediction, is a community-wide experiment for protein structure prediction taking place every two years since 1994. CASP provides with an opportunity to assess the quality of available human, non-automated methodology (human category) and automatic servers for protein structure prediction (server category, introduced in the CASP7). The CAMEO3D Continuous Automated Model EvaluatiOn Server evaluates automated protein structure prediction servers on a weekly basis using blind predictions for newly release protein structures. CAMEO publishes the results on its website.
Biotechnology has applications in four major industrial areas, including health care (medical), crop production and agriculture, non-food (industrial) uses of crops and other products (e.g., biodegradable plastics, vegetable oil, biofuels), and environmental uses. For example, one application of biotechnology is the directed use of microorganisms for the manufacture of organic products (examples include beer and milk products). Another example is using naturally present bacteria by the mining industry in bioleaching. Biotechnology is also used to recycle, treat waste, clean up sites contaminated by industrial activities (bioremediation), and also to produce biological weapons. A series of derived terms have been coined to identify several branches of biotechnology, for example:
Sources: en.wikipedia.org
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.
Mass spectrometry gives the molecular mass, which is compared with the calculated value. Reversed-phase liquid chromatography shows purity and the presence of related impurities. Peptide mapping can verify the amino acid sequence when a higher level of detail is needed.
It reports the tests the supplier performed, which may vary between laboratories and lots. Methods and acceptance criteria are not standardised across suppliers. Buyers often request the actual chromatograms and spectra rather than a summary statement.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.